wasa, I don't have an answer for you, hottod has posted such information in the past including non-US pharma companies. I prefer a big company because such a company has dealt with FDA in the past, it has had other medicines approved by FDA and because of that it has regulatory experience. Considering that there is strong interest for trofinetide ex-US rights, I would extrapolate it, hopefully, to strong interest from many big pharma for US rights or worldwide rights for nnz2591 after a successful P2 trials which may lead to a very good deal for 2591.
I come back to a logical statement, in my view, which I have made several times in my prior posts... Considering that trofinetide cleaves itself inside the brain in 2 components and one of these components is nnz2591, (second component is not so important in symptoms improvement), it is highly probable (if not 100%) that nnz2591 will also have successful trial results because trofinetide has already had good results in P3 trial. There may be other doctors at these big pharmas who may have a similar logical view now or after a successful P2 trial results for nnz2591 and this may lead to a strong competition to acquire 2591 rights. (by the way, I am not a doctor)
NEU Price at posting:
$3.94 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)